BC Week In Review | Oct 27, 2014
Clinical News

Lutonix 035 Drug Coated Balloon PTA Catheter regulatory update

FDA approved a PMA from C.R. Bard for Lutonix 035 Drug Coated Balloon PTA Catheter for percutaneous transluminal angioplasty, after pre-dilation, of de novo or restenotic lesions up to 150 mm in length in native...
BC Week In Review | Dec 9, 2013
Clinical News

Lutonix Drug Coated PTA Dilatation Catheter regulatory update

C.R. Bard submitted the final module of a PMA to FDA for Lutonix Drug Coated PTA Dilatation Catheter (DCB) to treat peripheral arterial disease (PAD) in superficial femoral (SFA) and popliteal arteries. Bard markets the...
BC Week In Review | Jun 17, 2013
Clinical News

Moxy Drug-Coated Balloon: Phase III started

C.R. Bard began the single-blind, international Phase III Lutonix Below the Knee (BTK) trial to compare its Lutonix Drug Coated PTA Dilatation Catheter (DCB) vs. a standard angioplasty balloon in about 480 patients. The product...
BC Week In Review | Jul 30, 2012
Clinical News

Moxy Drug-Coated Balloon: Completed Phase II enrollment

Bard's Lutonix technology center completed enrollment of 476 patients with diseased femoropopliteal leg arteries in the single-blind, international, pivotal Phase II LEVANT 2 trial evaluating its Lutonix Drug Coated PTA Dilatation Catheter (DCB) vs. a...
BC Week In Review | Jan 2, 2012
Company News

C.R. Bard, Lutonix deal

Bard acquired Lutonix for $225 million in cash plus an additional $100 million based on FDA approval of a PMA for Lutonix's Moxy Drug-Coated Balloon . The paclitaxel-coated balloon catheter is in a pivotal trial to...
BC Week In Review | Aug 1, 2011
Clinical News

Moxy Drug-Coated Balloon: Pivotal trial started

Lutonix began the international pivotal LEVANT 2 trial to evaluate its Moxy Drug-Coated Balloon vs. standard angioplasty balloon in about 476 patients. Lutonix Inc. , Maple Grove, Minn.   Product: Moxy Drug-Coated Balloon   Business: Cardiovascular...
BC Week In Review | Jul 4, 2011
Company News

Lutonix management update

Lutonix Inc. , Maple Grove, Minn.   Business: Cardiovascular   Hired: Shawn McCormick as COO, formerly CFO of ev3 Inc.; and Leslie Trigg as EVP of marketing and commercial strategy, formerly CBO of AccessClosure Inc.  ...
Items per page:
1 - 7 of 7
BC Week In Review | Oct 27, 2014
Clinical News

Lutonix 035 Drug Coated Balloon PTA Catheter regulatory update

FDA approved a PMA from C.R. Bard for Lutonix 035 Drug Coated Balloon PTA Catheter for percutaneous transluminal angioplasty, after pre-dilation, of de novo or restenotic lesions up to 150 mm in length in native...
BC Week In Review | Dec 9, 2013
Clinical News

Lutonix Drug Coated PTA Dilatation Catheter regulatory update

C.R. Bard submitted the final module of a PMA to FDA for Lutonix Drug Coated PTA Dilatation Catheter (DCB) to treat peripheral arterial disease (PAD) in superficial femoral (SFA) and popliteal arteries. Bard markets the...
BC Week In Review | Jun 17, 2013
Clinical News

Moxy Drug-Coated Balloon: Phase III started

C.R. Bard began the single-blind, international Phase III Lutonix Below the Knee (BTK) trial to compare its Lutonix Drug Coated PTA Dilatation Catheter (DCB) vs. a standard angioplasty balloon in about 480 patients. The product...
BC Week In Review | Jul 30, 2012
Clinical News

Moxy Drug-Coated Balloon: Completed Phase II enrollment

Bard's Lutonix technology center completed enrollment of 476 patients with diseased femoropopliteal leg arteries in the single-blind, international, pivotal Phase II LEVANT 2 trial evaluating its Lutonix Drug Coated PTA Dilatation Catheter (DCB) vs. a...
BC Week In Review | Jan 2, 2012
Company News

C.R. Bard, Lutonix deal

Bard acquired Lutonix for $225 million in cash plus an additional $100 million based on FDA approval of a PMA for Lutonix's Moxy Drug-Coated Balloon . The paclitaxel-coated balloon catheter is in a pivotal trial to...
BC Week In Review | Aug 1, 2011
Clinical News

Moxy Drug-Coated Balloon: Pivotal trial started

Lutonix began the international pivotal LEVANT 2 trial to evaluate its Moxy Drug-Coated Balloon vs. standard angioplasty balloon in about 476 patients. Lutonix Inc. , Maple Grove, Minn.   Product: Moxy Drug-Coated Balloon   Business: Cardiovascular...
BC Week In Review | Jul 4, 2011
Company News

Lutonix management update

Lutonix Inc. , Maple Grove, Minn.   Business: Cardiovascular   Hired: Shawn McCormick as COO, formerly CFO of ev3 Inc.; and Leslie Trigg as EVP of marketing and commercial strategy, formerly CBO of AccessClosure Inc.  ...
Items per page:
1 - 7 of 7